Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Urokinase plasminogen activator surface receptor (uPAR, encoded by the PLAUR gene) is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that plays a central role in regulating pericellular proteolysis, cell migration, and tissue remodeling. By binding its primary ligand, urokinase-type plasminogen activator (uPA), uPAR localizes and accelerates the conversion of plasminogen to plasmin, initiating a proteolytic cascade that degrades the extracellular matrix. Beyond its proteolytic functions, uPAR acts as a signaling hub by forming lateral complexes with transmembrane co-receptors, such as integrins, G-protein coupled receptors, and EGFR, thereby activating downstream FAK/Src, MAPK, and PI3K/Akt pathways to promote cell survival, proliferation, and epithelial-mesenchymal transition.
In pathological contexts, uPAR is highly overexpressed in various solid tumors (including breast, prostate, pancreatic, and ovarian cancers, as well as glioblastoma) and is strongly associated with tumor invasion, metastasis, angiogenesis, and poor patient prognosis. It is also a marker of cellular senescence and is implicated in chronic inflammatory, fibrotic, and cardiovascular diseases. Therapeutic strategies targeting uPAR include monoclonal antibodies (such as huATN-658) that disrupt uPAR-integrin signaling, uPAR-targeted CAR-T cells designed to eliminate both tumor cells and senescent/suppressive stromal cells, and radiolabeled peptides (such as 64Cu-DOTA-AE105) for PET imaging and targeted radionuclide therapy. However, drug development faces challenges such as potential on-target/off-tumor toxicities due to low-level uPAR expression in normal tissues (e.g., endothelial cells, leukocytes, and renal tubules) and the shedding of active soluble uPAR (suPAR).
Inhibition of uPAR-integrin interaction, disruption of uPA-uPAR binding, targeted cellular cytotoxicity via CAR-T cells, and targeted radionuclide imaging or therapy
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Urokinase plasminogen activator surface receptor (uPAR).